

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

) Art Unit:

3762

Application of : Sacher, F. et al

U.S. Appln. No. : 10/743,225) Examiner: Confirmation No. : 7664 U.S. Filing Date : 12/22/2003 Title of Invention : Method of Improvement of Blood Circulat Attny. Docket No.: 1/1444US	
Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450	
April 15, 2004	
TRANSMITTAL LETTER FOR INFORMATION DISC	CLOSURE STATEMENT
Sir:	
Transmitted herewith concerning the subject application is an In Statement (Form 1449A/B) under 37 C.F.R. §§1.56 and 1.97, we patent references cited therein and as more specifically described	vith copies of all non-US
1.97(b). This Statement is being filed: i) within the date of a national application other than a continued prosecution §1.53 (d); ii) within three (3) months of the date of entry of the 37 C.F.R. §1.491 in an international application; iii) before the on the merits; or iv) before the mailing of a first Office action a continued examination under 37 C.F.R. §1.114.	n application under 33 C.F.R. national stage as set forth in mailing of a first Office action
1.97(c). This Statement is being filed after the time C.F.R. §1.97(b), but before the mailing date of: i) a final action notice of allowance under 37 C.F.R. §1.311, or iii) an action that in the application. This Statement is being accompanied by:	under 37 C.F.R. §1.113, ii) a
A statement as specified in 37 C.F.R. §1.97(e) [see below]; or
The fee set forth in 37 C.F.R. §1.17(p).	
The Commissioner is hereby authorized (\$180.00 fee set forth in 37 C.F.R. §1.17(p) to De 02-2955.	

	ent as sp	This Statement is being filed after the period specified in 37 C.F.R. n or before payment of the issue fee. This Statement is accompanied by a pecified in 37 C.F.R. §1.97(e) [see below] and the fee set forth in 37 C.F.R.
	1.97(e)).
	counte	Each item of information contained in the instant information disclosure ent was first cited in any communication from a foreign patent office in a rpart foreign application not more than three (3) months prior to the filing of the information disclosure statement; or
	foreign making disclos	No item of information contained in the instant information disclosure ent was cited in a communication from a foreign patent office in a counterpart application, and, to the knowledge of the person signing this certification after greasonable inquiry, no item of information contained in the instant information sure statement was known to any individual designated in 37 C.F.R. §1.56(c) than three (3) months prior to the filing of the instant information disclosure ent.
		The fee set forth in 37 C.F.R. §1.17(p).
		The Commissioner is hereby authorized to charge payment of the \$180.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955.
counte	rpart ap ion 1.56	d). Each item of information contained in the accompanying information tement was cited in a communication from a foreign patent office in a oplication, which communication was not received by any individual designated $\delta(c)$ more than thirty (30) days prior to the filing of the accompanying isclosure statement.
	quired ı	ommissioner is hereby authorized to charge payment of any additional filing under 37 C.F.R. §1.16 and any patent application processing fees under 37 or credit any overpayment of same, to Deposit Account No. 02-2955.

Triplicate copies of this form are enclosed.

Respectfully submitted,

Andrea D. Small

Attorney for Applicant(s)

Reg. No. 54,859

Patent Department Boehringer Ingelheim Corp. 900 Ridgebury Road, P.O. Box 368 Ridgefield, CT 06877

Tel: (203) 798-4816 Date: April 15, 2004 Certificate of Mailing

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:

Commissioner For Patents P. O. Box 1450 Alexandria, VA 22313-1450

on April 15, 2004.

Andrea D. Small, Reg. No. 54,859

PTO/SB/08a (08-03) Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE nder the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known Application Number 10/743,225 Filing Date 12/22/2003 First Named Inventor SACHER, F. et al Art Unit 3762 **Examiner Name**

(Use as many sheets as necessary)

Substitute for form 1449A/PTO

Attorney Docket Number 1/1444US 1

			U. S. PATENT I	OCUMENTS	
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ^{2 (f known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
•		^{US-} 6,485,727 B1	11/26/2002	Esperester, A. et al	
		US-	•		
	i	US-			
		US-			
		us-			
		US-	-		
		US-			
····· 	-	US-			
		US-	***************************************		
		US-			

	FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	T€
	├	Country Code ³ Number ⁴ Kind Code ⁵ (# known)	06/17/1000	Indena, S.P.A.	or Relevant Figures Appear	┢
		WO 99/29331	06/17/1999			├
• • • • • • • • • • • • • • • • • • • •	ļ	EP 0694305 A1	01/31/1996	Indena, S.P.A.	***************************************	<u> </u>
	<u> </u>	GB 934,554	08/21/1963	Abeles, E.		辶
	1					

Examiner Signature Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	Substitute for	form 1449B/PTO				Complete if Known	1
					Application Number	10/743,225	_
	INFOF	RMATION DI	SCLO	SURE	Filing Date	12/22/2003	_
	STATI	EMENT BY A	APPLI	CANT	First Named Inventor	SACHER, F. et al	_
					Art Unit	3762	_
	((Use as many sheets as	necessary)	Examiner Name		_
abla	Sheet	2	of	2	Attorney Docket Number	1/1444US	J

		NON PATENT LITERATURE DOCUMENTS
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
		Endotelon, Medecine et Hygiene (1989), 47/1797 (1826)* GIRRE, L, et al; In Vitro Antiherpetic Activity of the leaves of the Red Vine Vitis-Vinifera, Fitoerapia, vol. 61, No. 3, 1990, pp 201-206, XP000981757 IDB Holding, Milan, It. ISSN 0367-326 p.201-p.202
		Database Medline Online US National Library of Medicine (NLM) Bethesda, MD US: CON\STANTINI, A et al; Clinical and Capillaroscopic Evaluation of Chronic Uncompliated Venous Insufficiency with Procyanidins Extracted from Vitis Vinifera XP 002159795, January 1999
		•

Examiner	<u></u>	Date

Considered Signature *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

considered. Include copy of this form with next communication to applicant. considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.